• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jul 28, 2023 at 11:52: AM
via The first half of 2023 saw the first approvals of therapies for a genetic subset of ALS and a pair of rare neurological disorders, Rett syndrome and Friedreich’s ataxia—and the regulator has several decisions for rare and orphan diseases on the docket in the second half of the year.

article source
 




Top Bottom
Back
Quote